Most Validated AI Therapeutic Design Platform
Ainnocence is a global biotech company that leads in generative AI for therapeutic discovery, leveraging industry grade sequence-based proprietary technology and training data from over 16 years expertise.
Problem:
Costly high throughput wet lab screening, expensive structure biology and inaccurate 3D modeling processes.
Solution:
A radical AI drug discovery system that accelerates the discovery of life-saving therapies with unprecedented speed, large and deep virtual throughput and higher success rates, for all therapeutic targets.
- Industry Grade Proprietary AI software system and training data
- Virtual screening capabilities up to 10 billions with unlimited computational scalability for multi-targets and multi-objective optimization
- 10%-60% hit rate on wet lab validation.
- 60+ successful deliveries with wet lab validation
- Reducing wet lab iteration for lead optimization from traditionally 1000-millions to less than 100 candidate molecules, over 80% cost reduction.
- Revolutionizing drug design to tackle previously undruggable or 3D structure unknown targets, 75% expanded therapeutic target space.
- Expanding drug intellectual property spaces.
- Rescuing failed clinical trials.
Optimizing Therapeutic Discovery with AI EnabledProcesses Supporting All Modelities
Ainnocence’s discovery platform is a proprietary, sequence-based AI system developed entirely in-house.
By working directly from primary sequence data, it eliminates the need for external 3-D structure-prediction software and other open-source packages. Instead, our technology performs ultra-high-throughput virtual screening and multi-objective optimisation, evaluating up to 10¹⁰ candidates within hours to days—giving our partners capabilities that off-the-shelf tools cannot match.
Have questions?
Get in touch!
Empowering Industry Leaders Globally
Sponsored By AI partners